SOMERSET, N.J., March 8 /PRNewswire-FirstCall/ -- Ventiv Health, Inc. today announced that it has signed a new agreement that expands its existing relationship with Boehringer Ingelheim. Through this agreement, Ventiv will provide a sales team and supporting sales management to support Boehringer’s well-established primary care sales organization. In connection with this deployment, Ventiv will also provide BI a full suite of sales and marketing services to support this expanded sales effort.
Terrell Herring, President and CEO of Ventiv Commercial Services, said, “We have had the privilege of working with BI on several different business initiatives over the past eight years, and are very pleased that they have once again selected Ventiv to support their existing national primary care sales force. This relationship is an important example of Ventiv’s ability to continuously provide flexible, customized solutions to help our clients achieve success.”
Mike Leonetti, Head of Alliances and Partnerships for BI, said, “Ventiv is a very client-focused organization and has worked closely with us to provide a variety of business solutions to achieve our goals. We are pleased to be working with them again as our partner of choice for this important initiative.”
About Boehringer Ingelheim
The Boehringer Ingelheim group is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 144 affiliates in 45 countries and nearly 36,000 employees. Since it was founded in 1885, the privately-owned company has been committed to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine. For more information, please visit http://www.boehringer-ingelheim.com.
About Ventiv Health
Ventiv Health, Inc. is the leading provider of commercialization and complementary services to the global pharmaceutical, life sciences and biotechnology industries. Ventiv delivers its customized clinical, sales, marketing and communications solutions through its three core business segments: Ventiv Commercial, Ventiv Clinical and Ventiv Communications. Ventiv works with over 150 pharmaceutical and life sciences clients, including 18 of top 20 global pharmaceutical companies. For more information, visit http://www.ventiv.com.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks that may cause Ventiv Health’s performance to differ materially. Such risks include, without limitation: changes in trends in the pharmaceutical industry or in pharmaceutical outsourcing; our ability to compete successfully with other services in the market; our ability to maintain large client contracts or to enter into new contracts; and, our ability to operate successfully in new lines of business. Readers of this press release are referred to documents filed from time to time by Ventiv Health, Inc. with the Securities and Exchange Commission for further discussion of these and other factors.
Ventiv Health, Inc.
CONTACT: Investors/Corporate: John Emery, CFO, +1-732-537-4804,investor@ventiv.com, or Media: Felicia Vonella, +1-212-308-7155,fvonella@ventiv.com, both of Ventiv Health, Inc.
